These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11383372)

  • 1. Should all patients with cardiovascular disease receive statin therapy?
    Vogel R; Schaefer E
    Am J Manag Care; 2001 May; 7(5 Suppl):S117-24. PubMed ID: 11383372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
    Rosenson RS
    Am Heart J; 2006 Mar; 151(3):556-63. PubMed ID: 16504615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In face of the increasing efficacy of lipid-lowering therapy, is there still a place for LDL-apheresis?
    Stegmayr B; Lalau JD; Johnson O
    Transfus Apher Sci; 2004 Jun; 30(3):213-20. PubMed ID: 15172626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins--similarities and differences.
    Pedersen T; Gaw A
    Am J Manag Care; 2001 May; 7(5 Suppl):S132-7. PubMed ID: 11383374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What do the statin trials tell us?
    Waters DD
    Am J Manag Care; 2001 May; 7(5 Suppl):S138-43. PubMed ID: 11383375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Threshold level or not for low-density lipoprotein cholesterol.
    Barter PJ; Sacks FM
    Am J Manag Care; 2001 May; 7(5 Suppl):S125-31. PubMed ID: 11383373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of treatment of children and adolescents with elevated low density lipoprotein levels with a step two diet or with lovastatin.
    Kwiterovich PO
    Nutr Metab Cardiovasc Dis; 2001 Oct; 11 Suppl 5():30-4. PubMed ID: 12063773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: an analysis of patient data from a Maryland-based health maintenance organization.
    Cooke CE; Hammerash WJ
    Clin Ther; 2006 Apr; 28(4):591-9. PubMed ID: 16750470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin and ezetimibe combination therapy in cardiovascular disease.
    Dembowski E; Davidson MH
    Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):183-8. PubMed ID: 19262375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of statin therapy in patients with preexisting liver disease.
    Onofrei MD; Butler KL; Fuke DC; Miller HB
    Pharmacotherapy; 2008 Apr; 28(4):522-9. PubMed ID: 18363535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
    Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-density lipoprotein size and cardiovascular risk assessment.
    Rizzo M; Berneis K
    QJM; 2006 Jan; 99(1):1-14. PubMed ID: 16371404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
    Robinson JG
    Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.